The shortage of Novo Nordisk’s (NVO) blockbuster diabetes and weight-loss drugs is officially over, according to the U.S.

Blockbuster weight-loss and diabetes drugs Wegovy and Ozempic are no longer in shortage, the US Food and Drug Administration ...

Federal regulators say shortages of Ozempic and Wegovy have been resolved, as supplies of popular diabetes and obesity ...

But 25-year-old Madison Burgess has thrown caution to the wind by opting to micro-dose the drug. The Michigan native revealed ...

The FDA’s decision will threaten the ability of compounding pharmacies to make far cheaper, unbranded versions of the ...

The agency first declared a shortage of semaglutide, the main ingredient used to make Ozempic and Wegovy, in 2022.

Though not approved by the Food and Drug Administration (FDA) for obesity ... Medications containing semaglutide marketed for type 2 diabetes or weight loss. Centers for Disease Control and Prevention ...

Clinic Secret prescribes GLP-1 medications, including semaglutide and tirzepatide. These medications are FDA-approved and can be effective for weight loss and blood sugar control. Are the ...

contains the same active ingredient as the brand-name medications (but it hasn’t been approved by the FDA). As a weight loss drug, semaglutide is intended to be used along with lifestyle changes ...

In addition, the Company is pleased to report that it has received HREC approval ... semaglutide as is being explored in Arm 2, might offer some benefit of improved weight loss and/or reduced ...